메뉴 건너뛰기




Volumn 38, Issue 12, 2015, Pages 2217-2225

New insulin glargine 300Units/mL versus glargine 100 Units/mL in people with type 1 diabetes: A randomized, phase 3a, open- label clinical trial (EDITION 4)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

EID: 84962432685     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0249     Document Type: Article
Times cited : (169)

References (20)
  • 2
    • 84892649479 scopus 로고    scopus 로고
    • Standards of medical care in diabetesd2014
    • American Diabetes Association.
    • American Diabetes Association. Standards of medical care in diabetesd2014. Diabetes Care 2014;37(Suppl. 1):S14-S80.
    • (2014) Diabetes Care , vol.37 , pp. S14-S80
  • 3
    • 0034033028 scopus 로고    scopus 로고
    • Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study group of insulin glargine in type 1 diabetes
    • Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000;23:639-643.
    • (2000) Diabetes Care , vol.23 , pp. 639-643
    • Ratner, R.E.1    Hirsch, I.B.2    Neifing, J.L.3    Garg, S.K.4    Mecca, T.E.5    Wilson, C.A.6
  • 4
    • 0038418746 scopus 로고    scopus 로고
    • Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart
    • Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-596.
    • (2003) Diabetes Care , vol.26 , pp. 590-596
    • Vague, P.1    Selam, J.L.2    Skeie, S.3
  • 5
    • 84879274635 scopus 로고    scopus 로고
    • Most youth with type 1 diabetes in the T1D exchange clinic registry do not meet American diabetes association or international society for pediatric and adolescent diabetes clinical guidelines
    • T1D Exchange Clinic Network
    • Wood JR, Miller KM, Maahs DM, et al.; T1D Exchange Clinic Network. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 2013;36:2035-2037.
    • (2013) Diabetes Care , vol.36 , pp. 2035-2037
    • Wood, J.R.1    Miller, K.M.2    Maahs, D.M.3
  • 6
    • 84866559820 scopus 로고    scopus 로고
    • Evolution of insulin development: Focus on key parameters
    • Tibaldi JM. Evolution of insulin development: focus on key parameters. Adv Ther 2012;29:590-619.
    • (2012) Adv Ther , vol.29 , pp. 590-619
    • Tibaldi, J.M.1
  • 7
    • 80054081129 scopus 로고    scopus 로고
    • Optimizing the replacement of basal insulin in type 1 diabetes mellitus: No longer an elusive goal in the post-NPH era
    • Bolli GB, Andreoli AM, Lucidi P. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 2011;13 (Suppl. 1):S43-S52.
    • (2011) Diabetes Technol Ther , vol.13 , pp. S43-S52
    • Bolli, G.B.1    Andreoli, A.M.2    Lucidi, P.3
  • 8
    • 84929019522 scopus 로고    scopus 로고
    • New insulin glargine 300 unitszmL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 unitszmL-1
    • Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 unitszmL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 unitszmL-1. Diabetes Care 2015;38:637-643.
    • (2015) Diabetes Care , vol.38 , pp. 637-643
    • Becker, R.H.1    Dahmen, R.2    Bergmann, K.3    Lehmann, A.4    Jax, T.5    Heise, T.6
  • 9
    • 84908179629 scopus 로고    scopus 로고
    • Newinsulin glargine 300 units/Ml versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (Edition 1)
    • Home PD; EDITION 1 Study Investigators
    • Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD; EDITION 1 Study Investigators. Newinsulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37:2755-2762.
    • (2014) Diabetes Care , vol.37 , pp. 2755-2762
    • Riddle, M.C.1    Bolli, G.B.2    Ziemen, M.3    Muehlen-Bartmer, I.4    Bizet, F.5
  • 10
    • 84910033227 scopus 로고    scopus 로고
    • New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (Edition 2)
    • EDITION 2 Study Investigators
    • Yki-Järvinen H, Bergenstal R, Ziemen M, et al.; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014; 37:3235-3243.
    • (2014) Diabetes Care , vol.37 , pp. 3235-3243
    • Yki-Järvinen, H.1    Bergenstal, R.2    Ziemen, M.3
  • 11
    • 84922186708 scopus 로고    scopus 로고
    • New insulin glargine 300 u/mL: Glycemic control and hypoglycemia in Japanese people with T1DM (edition JP 1) (Abstract)
    • EDITION JP1 study group
    • Matsuhisa M, Koyama M, Cheng XN, Shimizu S, Hirose T. EDITION JP1 study group. New insulin glargine 300 U/mL: glycemic control and hypoglycemia in Japanese people with T1DM (EDITION JP 1) (Abstract). Diabetes 2014;63(Suppl. 1A):LB22.
    • (2014) Diabetes , vol.63 , pp. LB22
    • Matsuhisa, M.1    Koyama, M.2    Cheng, X.N.3    Shimizu, S.4    Hirose, T.5
  • 12
    • 18144388647 scopus 로고    scopus 로고
    • Defining and reporting hypoglycemia in diabetes: A report from the American diabetes association workgroup on hypoglycemia
    • Workgroup on Hypoglycemia, American Diabetes Association
    • Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249.
    • (2005) Diabetes Care , vol.28 , pp. 1245-1249
  • 13
    • 0023942705 scopus 로고
    • A measure of treatment satisfaction designed specifically for people with insulin dependent diabetes
    • Lewis KS, Bradley C, Knight G, Boulton AJ, Ward JD. A measure of treatment satisfaction designed specifically for people with insulindependent diabetes. DiabetMed 1988;5:235-242.
    • (1988) DiabetMed , vol.5 , pp. 235-242
    • Lewis, K.S.1    Bradley, C.2    Knight, G.3    Boulton, A.J.4    Ward, J.D.5
  • 14
    • 0025688231 scopus 로고
    • Euroqolda new facility for the measurement of health-related quality of life
    • Euro Qol Group
    • Euro Qol Group. EuroQolda new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
    • (1990) Health Policy , vol.16 , pp. 199-208
  • 16
    • 34147116068 scopus 로고    scopus 로고
    • Optimized use of insulin glargine in intensive treatment of type 1 diabetes mellitus: Benefits and a new question (Abstract)
    • Porcellati F, Rossetti P, Fanelli C, Bolli GB. Optimized use of insulin glargine in intensive treatment of type 1 diabetes mellitus: Benefits and a new question (Abstract). Diabetes 2005; 54:524P.
    • (2005) Diabetes , vol.54 , pp. 524
    • Porcellati, F.1    Rossetti, P.2    Fanelli, C.3    Bolli, G.B.4
  • 17
    • 84905721701 scopus 로고    scopus 로고
    • Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes
    • Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RH. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014;16:873-876.
    • (2014) Obes Metab , vol.16 , pp. 873-876
    • Steinstraesser, A.1    Schmidt, R.2    Bergmann, K.3    Dahmen, R.4    Becker, R.H.5
  • 18
    • 84982213135 scopus 로고    scopus 로고
    • Insulin glargine 300 U/ml vs 100 u/mL: Glucose profiles of morning vs evening injections in adults with type 1 diabetes mellitus measured with continuous glucose monitoring (CGM) (abstract number 949)
    • Bergenstal RM, Bailey TS, Rodbard D, et al. Insulin glargine 300 U/ml vs 100 U/ml: glucose profiles of morning vs evening injections in adults with type 1 diabetes mellitus measured with continuous glucose monitoring (CGM) (Abstract Number 949). Diabetologia 2014;57 (Suppl.):388-389.
    • (2014) Diabetologia , vol.57 , pp. 388-389
    • Bergenstal, R.M.1    Bailey, T.S.2    Rodbard, D.3
  • 19
    • 84924731879 scopus 로고    scopus 로고
    • New insulin glargine 300 U/ mL compared with glargine 100 u/ml in insulin-näive people with type 2 diabetes on oral glucose-lowering drugs: Glucose control and hypoglycemia in a randomized controlled trial (EDITION 3)
    • Bolli GB, Riddle MC, Bergenstal R, et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-näive people with type 2 diabetes on oral glucose-lowering drugs: glucose control and hypoglycemia in a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015;17:386-394.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 386-394
    • Bolli, G.B.1    Riddle, M.C.2    Bergenstal, R.3
  • 20
    • 84907205890 scopus 로고    scopus 로고
    • Unhelpful information about adverse drug reactions
    • Tan K, Petrie KJ, Faasse K, Bolland MJ, Grey A. Unhelpful information about adverse drug reactions. BMJ 2014;349:g5019.
    • (2014) BMJ , vol.349 , pp. g5019
    • Tan, K.1    Petrie, K.J.2    Faasse, K.3    Bolland, M.J.4    Grey, A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.